Published in Best Pract Res Clin Endocrinol Metab on June 01, 2012
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J (2016) 1.11
Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci (2014) 1.03
Graves' orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J (2013) 0.90
Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins. J Clin Endocrinol Metab (2014) 0.85
Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy. Dis Markers (2015) 0.83
Lack of Association between Selenium Status and Disease Severity and Activity in Patients with Graves' Ophthalmopathy. Eur Thyroid J (2016) 0.83
Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy. Med Sci Monit (2014) 0.82
TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. J Clin Endocrinol Metab (2016) 0.79
An overview of thyroid eye disease. Eye Vis (Lond) (2014) 0.78
[Update on endocrine orbitopathy]. Ophthalmologe (2013) 0.78
News and views: at long last, an animal model of Graves' orbitopathy. Endocrinology (2013) 0.77
Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy. J Endocrinol Invest (2015) 0.77
Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment. Eur Thyroid J (2014) 0.76
Does autoimmunity against thyroglobulin play a role in the pathogenesis of Graves' ophthalmopathy: a review. Clin Ophthalmol (2015) 0.76
Mesenchymal Stem Cell-Like Properties of Orbital Fibroblasts in Graves' Orbitopathy. Invest Ophthalmol Vis Sci (2015) 0.75
Benzylideneacetophenone derivatives attenuate IFN-γ-induced IP-10/CXCL10 production in orbital fibroblasts of patients with thyroid-associated ophthalmopathy through STAT-1 inhibition. Exp Mol Med (2014) 0.75
Growth hormone and insulin-like growth factor 1 affect the severity of Graves' disease. Endocrinol Diabetes Metab Case Rep (2017) 0.75
Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface. Clin Diabetes Endocrinol (2016) 0.75
Clinical practice. Graves' disease. N Engl J Med (2008) 5.78
Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov (2002) 2.73
Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev (2003) 2.23
Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet (1993) 2.13
Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2009) 2.10
Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab (2006) 1.92
Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol (2003) 1.75
Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2002) 1.74
The thyrotropin receptor in Graves' disease. Thyroid (2007) 1.65
Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol (2003) 1.61
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) (2000) 1.61
Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev (1989) 1.51
Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol (2003) 1.51
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol (2008) 1.45
Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab (2004) 1.45
Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39
A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab (2010) 1.37
Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol (2002) 1.36
Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology (1986) 1.33
Insight into Graves' hyperthyroidism from animal models. Endocr Rev (2005) 1.31
Insulin-like growth factor-I regulates pro-B cell differentiation. Blood (1992) 1.29
Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol (2002) 1.26
Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab (2006) 1.26
Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest (1993) 1.24
Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid (1993) 1.23
Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem (1998) 1.22
Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid (2008) 1.21
Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol (2007) 1.20
Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid (2002) 1.18
Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem (2009) 1.15
Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci (2006) 1.14
Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther (2011) 1.10
Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol (2000) 1.09
Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab (2012) 1.08
Insulin-like growth factor-I binds selectively to human peripheral blood monocytes and B-lymphocytes. J Clin Endocrinol Metab (1991) 1.07
Development of an animal model of autoimmune thyroid eye disease. J Immunol (1999) 1.05
Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol (1995) 1.03
Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation (2003) 1.02
Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (1999) 1.02
Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology (2001) 1.02
Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology (1996) 1.00
Adenosine 3',5'-monophosphate mediates both the mitogenic effect of thyrotropin and its ability to amplify the response to insulin-like growth factor I in FRTL5 cells. Endocrinology (1988) 0.98
Thyrotropin potentiation of insulin-like growth factor-I dependent deoxribonucleic acid synthesis in FRTL-5 cells: mediation by an autocrine amplification factor(s). Endocrinology (1990) 0.98
Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J Biol Chem (1996) 0.98
Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab (2011) 0.96
Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol (2004) 0.96
Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy. Endocrinology (2004) 0.96
Insulin-like growth factor-I stimulates IL-10 production in human T cells. J Leukoc Biol (2004) 0.96
B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol (2008) 0.96
Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem (2006) 0.95
Growth hormone and insulin-like growth factor I induce immunoglobulin (Ig)E and IgG4 production by human B cells. J Exp Med (1994) 0.94
Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity (1993) 0.94
Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol (2011) 0.93
Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology (2001) 0.92
Absence of hyaluronidase in cultured human skin fibroblasts. Biochem Biophys Res Commun (1975) 0.92
Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. Proc Natl Acad Sci U S A (1998) 0.92
Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts. J Clin Endocrinol Metab (1989) 0.91
Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease. J Biol Chem (2011) 0.91
Insulin-like growth factor-1 controls type 2 T cell-independent B cell response. J Immunol (2005) 0.89
The insulin-like growth factor system in hematopoietic cells. Leuk Lymphoma (2002) 0.89
Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology (2006) 0.88
In vivo administration of insulin-like growth factor-I stimulates primary B lymphopoiesis and enhances lymphocyte recovery after bone marrow transplantation. J Immunol (1994) 0.88
Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology (1992) 0.88
HMC-1 mast cells activate human orbital fibroblasts in coculture: evidence for up-regulation of prostaglandin E2 and hyaluronan synthesis. Endocrinology (1999) 0.88
Production of hyaluronan and chondroitin sulphate proteoglycans from human arterial smooth muscle--the effect of glucose, insulin, IGF-I or growth hormone. Eur J Endocrinol (2001) 0.87
IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase. Cell Signal (2003) 0.87
Immunological effects of insulin-like growth factor-I--enhancement of immunoglobulin synthesis. Clin Exp Immunol (1994) 0.86
Characterization and regulations of the receptor for insulin-like growth factor-I in the FRTL-5 rat thyroid follicular cell line. Endocrinology (1987) 0.86
Analysis of changes in the percentage of B (CD19) and T (CD3) lymphocytes, subsets CD4, CD8 and their memory (CD45RO), and naive (CD45RA) T cells in children with immune and non-immune thyroid diseases. J Pediatr Endocrinol Metab (2003) 0.86
Effect of growth hormone and insulin-like growth factor-I on immunoglobulin production by and growth of human B cells. J Clin Endocrinol Metab (1994) 0.86
Thyrotropin and insulin-like growth factor I regulation of tyrosine phosphorylation in FRTL-5 cells. Interaction between cAMP-dependent and growth factor-dependent signal transduction. J Biol Chem (1991) 0.86
Differential expression of type I insulin-like growth factor receptors in different stages of human T cells. Eur J Immunol (1995) 0.85
Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun (1993) 0.85
IGF-1 down-regulates IFN-gamma R2 chain surface expression and desensitizes IFN-gamma/STAT-1 signaling in human T lymphocytes. Blood (2003) 0.84
Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells. J Clin Endocrinol Metab (1986) 0.84
Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells. Hum Immunol (2005) 0.83
Insulin-like growth factor I (IGF-I) enhances hyaluronic acid synthesis in rabbit pericardium. Biochim Biophys Acta (1989) 0.83
Insulin-like growth factor I promotes maturation and inhibits apoptosis of immature cord blood monocyte-derived dendritic cells through MEK and PI 3-kinase pathways. Pediatr Res (2003) 0.83
IGF-1 potentiation of IL-4-induced CD23/Fc(epsilon)RII expression in human B cells. Mol Cells (2003) 0.83
Demonstration of the production and physiological role of insulin-like growth factor II in rat thyroid follicular cells in culture. J Clin Invest (1988) 0.82
The role of adenosine 3',5'-monophosphate in the regulation of receptors for thyrotropin and insulin-like growth factor I in the FRTL5 rat thyroid follicular cell. Endocrinology (1988) 0.82
IGF-I affects glycosaminoglycan/proteoglycan synthesis in breast cancer cells through tyrosine kinase-dependent and -independent pathways. Biochimie (2004) 0.82
Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh) (1992) 0.81
Up-regulation of putative hyaluronan synthase mRNA by basic fibroblast growth factor and insulin-like growth factor-1 in human skin fibroblasts. J Dermatol Sci (2001) 0.81
Intramolecular and intermolecular spreading during the course of organ allograft rejection. Immunol Rev (1998) 0.81
IGF-1 stimulates synthesis of undersulfated proteoglycans and of hyaluronic acid by peritubular cells from immature rat testis. Biochim Biophys Acta (1997) 0.78
Effect of insulin-like growth factor-I on the synthesis and distribution of link protein and hyaluronan in explant cultures of articular cartilage. Biochim Biophys Acta (1992) 0.78
IGF-I potentiates interleukin-2 production in human peripheral T cells. J Endocrinol (1996) 0.77
Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves' disease: evidence for a phenotypic signature ascribable to nongenetic factors. J Clin Endocrinol Metab (2009) 0.76
Pathogenesis of Graves' disease: molecular analysis of anti-thyrotropin receptor antibodies. Endocr J (1997) 0.76
Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid (2012) 3.66
American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract (2010) 2.97
Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology (2011) 2.86
Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology (2009) 2.44
Comparing outcomes of enucleation and evisceration. Ophthalmology (2006) 2.30
The effects of recombinant human thyrotropin, in normal subjects and patients with goitre. Clin Endocrinol (Oxf) (2004) 2.02
The hydrogel lacrimal stent for dacryocystorhinostomy: preliminary experience. Ophthal Plast Reconstr Surg (2008) 2.01
High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab (2005) 1.86
B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab (2007) 1.84
Hyperthyroidism and psychiatric morbidity: evidence from a Danish nationwide register study. Eur J Endocrinol (2013) 1.61
Childhood exposure to phthalates: associations with thyroid function, insulin-like growth factor I, and growth. Environ Health Perspect (2010) 1.60
Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid (2013) 1.48
Epitope recognition patterns of thyroid peroxidase autoantibodies in healthy individuals and patients with Hashimoto's thyroiditis*. Clin Endocrinol (Oxf) (2008) 1.46
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol (2008) 1.45
Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease. Eur J Endocrinol (2005) 1.43
Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy. Arch Ophthalmol (2012) 1.40
Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol (2011) 1.39
Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab (2003) 1.37
Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev (2012) 1.34
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut (2008) 1.28
Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet (2009) 1.26
Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol (2006) 1.25
Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid (2008) 1.21
The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol (2006) 1.20
Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf) (2012) 1.20
Clinical review: Nonsurgical, image-guided, minimally invasive therapy for thyroid nodules. J Clin Endocrinol Metab (2013) 1.14
Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol (2010) 1.11
Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci (2008) 1.10
Major genetic influence on the regulation of the pituitary-thyroid axis: a study of healthy Danish twins. J Clin Endocrinol Metab (2004) 1.10
Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol (2008) 1.09
Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab (2012) 1.08
The impact of a TSH receptor gene polymorphism on thyroid-related phenotypes in a healthy Danish twin population. Clin Endocrinol (Oxf) (2007) 1.08
B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther (2007) 1.07
Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab (2011) 1.05
Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf) (2011) 1.04
High-intensity focused ultrasound to treat primary hyperparathyroidism: a feasibility study in four patients. AJR Am J Roentgenol (2010) 1.04
A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. Eur J Endocrinol (2011) 1.03
Facial recontouring with autogenous fat. Facial Plast Surg (2004) 1.01
Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. Eur J Immunol (2004) 1.01
A review of the evidence for and against increased mortality in hypothyroidism. Nat Rev Endocrinol (2012) 1.01
Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid (2006) 1.01
Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol (2009) 1.01
Endoscopic removal of nasoglabellar dermoid cysts. Ophthal Plast Reconstr Surg (2010) 1.00
Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing. Qual Life Res (2008) 1.00
Increased psychiatric morbidity before and after the diagnosis of hypothyroidism: a nationwide register study. Thyroid (2014) 0.99
A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol (2011) 0.98
Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci U S A (2012) 0.97
Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid (2013) 0.97
Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem (2006) 0.95
Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules - a randomised study. Eur J Endocrinol (2005) 0.95
Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab (2010) 0.95
Identification and consequences of polymorphisms in the thyroid hormone receptor alpha and beta genes. Thyroid (2008) 0.94
Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB. Invest Ophthalmol Vis Sci (2012) 0.94
"En-glove" lysis of lower eyelid retractors with AlloDerm and dermis-fat grafts in lower eyelid retraction surgery. Ophthal Plast Reconstr Surg (2011) 0.94
Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol (2011) 0.93
Randomized prospective study comparing a single radioiodine dose and a single laser therapy session in autonomously functioning thyroid nodules. Eur J Endocrinol (2007) 0.93
PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy. PLoS One (2010) 0.93
The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid (2011) 0.93
Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules: one versus three treatments. Thyroid (2006) 0.92
Treatment of lower eyelid retraction by expansion of the lower eyelid with hyaluronic Acid gel. Ophthal Plast Reconstr Surg (2007) 0.91
Establishment of a serum thyroid stimulating hormone (TSH) reference interval in healthy adults. The importance of environmental factors, including thyroid antibodies. Clin Chem Lab Med (2004) 0.91
Thyroid hormone transport and metabolism by organic anion transporter 1C1 and consequences of genetic variation. Endocrinology (2008) 0.90
Genetic and environmental interrelations between measurements of thyroid function in a healthy Danish twin population. Am J Physiol Endocrinol Metab (2006) 0.90
Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab (2014) 0.90
Genetic and environmental causes of individual differences in thyroid size: a study of healthy Danish twins. J Clin Endocrinol Metab (2004) 0.90
Low birth weight is not associated with thyroid autoimmunity: a population-based twin study. J Clin Endocrinol Metab (2006) 0.90
Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol (2007) 0.90
Use of hyaluronic Acid gel in the management of paralytic lagophthalmos: the hyaluronic Acid gel "gold weight". Ophthal Plast Reconstr Surg (2009) 0.89
Excess mortality in patients diagnosed with hypothyroidism: a nationwide cohort study of singletons and twins. J Clin Endocrinol Metab (2013) 0.89
Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab (2007) 0.89
The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials (2014) 0.89
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol (2006) 0.89
Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials (2013) 0.89
Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management. Saudi J Ophthalmol (2010) 0.89
Too early to dismiss Yersinia enterocolitica infection in the aetiology of Graves' disease: evidence from a twin case-control study. Clin Endocrinol (Oxf) (2008) 0.89
Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology (2006) 0.88
Benign solitary solid cold thyroid nodules: US-guided interstitial laser photocoagulation--initial experience. Radiology (2002) 0.88
Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a danish nationwide register-based cohort study of twins and singletons. J Clin Endocrinol Metab (2012) 0.88
Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab (2002) 0.88
Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol (2008) 0.88
The pathophysiology of thyroid eye disease. J Neuroophthalmol (2014) 0.88
Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. Thyroid (2007) 0.88
Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination. Qual Life Res (2009) 0.88
Substantial interobserver variation of thyroid volume and function by visual evaluation of thyroid (99m)Tc scintigraphy. Dan Med J (2014) 0.87
A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. Clin Immunol (2009) 0.87
Aesthetic lateral canthoplasty. Ophthal Plast Reconstr Surg (2010) 0.87
Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab (2004) 0.87
Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One (2013) 0.87
Establishment of reference distributions and decision values for thyroid antibodies against thyroid peroxidase (TPOAb), thyroglobulin (TgAb) and the thyrotropin receptor (TRAb). Clin Chem Lab Med (2006) 0.87
Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab (2008) 0.87
Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort. J Bone Miner Res (2014) 0.87
Interstitial laser photocoagulation (ILP) of benign cystic thyroid nodules--a prospective randomized trial. J Clin Endocrinol Metab (2013) 0.86
Orbital wall fracture repair using Seprafilm. Ophthal Plast Reconstr Surg (2009) 0.86
Aggregation of thyroid autoantibodies in first-degree relatives of patients with autoimmune thyroid disease is mainly due to genes: a twin study. Clin Endocrinol (Oxf) (2004) 0.86
Management of the nontoxic multinodular goiter in Latin America: comparison with North America and Europe, an electronic survey. J Clin Endocrinol Metab (2004) 0.86
Therapy: a new nonsurgical therapy option for benign thyroid nodules? Nat Rev Endocrinol (2009) 0.86
Long-term outcome following interstitial laser photocoagulation of benign cold thyroid nodules. Eur J Endocrinol (2011) 0.85
Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. Thyroid (2008) 0.85